BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $12 | $18 | $19 | $16 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $12 | $18 | $20 | $17 |
| Revenue | $3 | $2 | $2 | $2 |
| % Growth | 18% | 15.4% | 13.5% | – |
| Gross Profit | $2 | $2 | $2 | $1 |
| % Margin | 79.7% | 78% | 76% | 74.5% |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 22.8% | 12.7% | 12.7% | 2.6% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 15% | 6.9% | 6.8% | -3.5% |
| EPS Diluted | 2.21 | 0.88 | 0.75 | -0.35 |
| % Growth | 151.1% | 17.3% | 314.3% | – |
| Operating Cash Flow | $1 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |